Abstract: The present invention provides a 4-aminoquinazoline derivative having the chemical structure of the following formula, and the use thereof. It is demonstrated by the pharmacological experiment that, the compound or a salt thereof according to the present invention not only has distinct inhibitory effect on histone deacetylases, but also has stronger differentiation induction and anti-proliferative activities for certain tumor cells. It can be used in the treatment of cancers and diseases related to cell differentiation and proliferation. Excellent efficacy is observed especially for leukemia and a solid tumor. As demonstrated by the animal test, the compound or a salt thereof according to the present invention is less toxic.
Type:
Grant
Filed:
May 10, 2012
Date of Patent:
May 19, 2015
Assignees:
Shanghai Institute of Pharmaceutical Industry, Jiangsu Hengyi Pharmaceutical Co., Ltd.
Abstract: The present invention discloses a group of histone deacetylase inhibitors and use thereof. The histone deacetylase inhibitors are useful in the treatment of malignant tumors and the diseases associated with differentiation and proliferation.
Abstract: The present invention provides a 4-aminoquinazoline derivative having the chemical structure of the following formula, and the use thereof. It is demonstrated by the pharmacological experiment that, the compound or a salt thereof according to the present invention not only has distinct inhibitory effect on histone deacetylases, but also has stronger differentiation induction and anti-proliferative activities for certain tumor cells. It can be used in the treatment of cancers and diseases related to cell differentiation and proliferation. Excellent efficacy is observed especially for leukemia and a solid tumor. As demonstrated by the animal test, the compound or a salt thereof according to the present invention is less toxic.
Type:
Application
Filed:
May 10, 2012
Publication date:
August 21, 2014
Applicants:
SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY, JIANGSU HENGYI PHARMACEUTICAL CO. LTD.
Abstract: The present invention discloses an aralkyl substituted piperidine or piperazine derivative and the use of the derivative in preparation of medicaments for treating schizophrenia and correlative psychoneuroses. It is shown by pharmacological tests that the derivative of the present invention has better antischizophrenic effect and less toxicity. Said derivative is a free base or salt of the compound having the following general formula.
Type:
Grant
Filed:
July 28, 2008
Date of Patent:
February 18, 2014
Assignee:
Jiangsu Hengyi Pharmaceutical Co., Ltd.
Inventors:
Jianqi Li, Shaoping Peng, Wangping Cai, Kai Gao
Abstract: The present invention relates to an aralkyl alcohol piperidine derivative and use as antidepressant thereof. The said aralkyl alcohol piperidine derivative has a triple inhibition effect on the reuptaking of 5-HT, NA and DA. The derivative may be administered to the patient in need of such treatment in the form of composition by oral administration, injection and the like.
Type:
Grant
Filed:
June 8, 2009
Date of Patent:
December 31, 2013
Assignee:
Jiangsu Hengyi Pharmaceutical Co., Ltd.
Inventors:
Jianqi Li, Kai Gao, Wangping Cai, Yongyong Zheng